Roy D. Baynes
CIK: 0001680739
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (56 total)
- Aug 14, 2026AARD
Aardvark Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
45K shares- - Jun 26, 2026NTRA
Natera, Inc.
Award(A)Direct75 shares- - Jun 26, 2026NTRA
Natera, Inc.
Award(A)Direct1.6K shares- - Jun 12, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct4.5K shares at avg. $21.38$96K - Jun 12, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct4.5K shares at avg. $50.00$225K - May 19, 2026TVTX
Travere Therapeutics, Inc.
Award(A)Direct4K shares- - May 15, 2026NRIX
Nurix Therapeutics, Inc.
Award(A)DirectDirector Stock Option (right to buy)
31.3K shares- - May 5, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct4.5K shares at avg. $18.27$82K - May 5, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct4.5K shares at avg. $46.65$210K - May 1, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct9.8K shares at avg. $44.22$431K - May 1, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct9.8K shares at avg. $6.82$66K - Apr 24, 2026NTRA
Natera, Inc.
Award(A)Direct83 shares- - Apr 14, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct8K shares at avg. $17.94$144K - Apr 14, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct9K shares at avg. $15.43$139K - Apr 14, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct4.5K shares at avg. $18.27$82K - Apr 14, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct4.5K shares at avg. $21.38$96K - Apr 14, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct6.8K shares at avg. $17.11$115K - Apr 14, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct26K shares at avg. $41.07$1.1M - Apr 14, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct6.8K shares at avg. $42.12$284K - Apr 6, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct10K shares at avg. $33.00$330K - Apr 6, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct10K shares at avg. $26.52$265K - Mar 2, 2026EIKN
Eikon Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
134.1K shares- - Jan 30, 2026NTRA
Natera, Inc.
Award(A)Direct70 shares- - Nov 20, 2025NTRA
Natera, Inc.
Sale(S)Direct1.9K shares at avg. $224.89$424K - Nov 20, 2025NTRA
Natera, Inc.
Sale(S)Direct1.9K shares at avg. $223.90$425K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 14, 2026 |  AARD Aardvark Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 44,964 | - | - | Direct |
| Jun 26, 2026 |  NTRA Natera, Inc. | Award(A) | 75 | - | $0 | Direct |
| Jun 26, 2026 | NTRA Natera, Inc. | Award(A) | 1,571 | - | $0 | Direct |
| Jun 12, 2026 |  TVTX Travere Therapeutics, Inc. | Exercise(M) | 4,500 | $21.38 | $96,210 | Direct |
| Jun 12, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 4,500 | $50.00 | $225,000 | Direct |
| May 19, 2026 | TVTX Travere Therapeutics, Inc. | Award(A) | 4,000 | - | $0 | Direct |
| May 15, 2026 |  NRIX Nurix Therapeutics, Inc. | Award(A) Director Stock Option (right to buy) | 31,250 | - | - | Direct |
| May 5, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 4,500 | $18.27 | $82,215 | Direct |
| May 5, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 4,500 | $46.65 | $209,925 | Direct |
| May 1, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 9,750 | $44.22 | $431,145 | Direct |
| May 1, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 9,750 | $6.82 | $66,495 | Direct |
| Apr 24, 2026 | NTRA Natera, Inc. | Award(A) | 83 | - | $0 | Direct |
| Apr 14, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 8,000 | $17.94 | $143,520 | Direct |
| Apr 14, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 9,000 | $15.43 | $138,870 | Direct |
| Apr 14, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 4,500 | $18.27 | $82,215 | Direct |
| Apr 14, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 4,500 | $21.38 | $96,210 | Direct |
| Apr 14, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 6,750 | $17.11 | $115,493 | Direct |
| Apr 14, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 26,000 | $41.07 | $1,067,820 | Direct |
| Apr 14, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 6,750 | $42.12 | $284,310 | Direct |
| Apr 6, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 10,000 | $33.00 | $330,000 | Direct |
| Apr 6, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 10,000 | $26.52 | $265,200 | Direct |
| Mar 2, 2026 |  EIKN Eikon Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 134,088 | - | - | Direct |
| Jan 30, 2026 | NTRA Natera, Inc. | Award(A) | 70 | - | $0 | Direct |
| Nov 20, 2025 | NTRA Natera, Inc. | Sale(S) | 1,884 | $224.89 | $423,685 | Direct |
| Nov 20, 2025 | NTRA Natera, Inc. | Sale(S) | 1,900 | $223.90 | $425,417 | Direct |
1-25 of 56 transactions
About Baynes Roy D.
Baynes Roy D. (SEC CIK 0001680739) files insider reports with the SEC as Director of Aardvark Therapeutics, Inc. (AARD), Director of Natera, Inc. (NTRA) and Director of Travere Therapeutics, Inc. (TVTX). Signal8 also holds filings tied to 2 other companies.
Signal8 holds 29 ownership filings by Baynes Roy D. (3 Form 3, 26 Form 4), filed between Oct 29, 2024 and Aug 21, 2026. Those filings report 56 transactions, from Oct 25, 2024 to Aug 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Baynes Roy D.'s filings is in SAN DIEGO, CA.
Recent filings by Baynes Roy D.
- Aug 14, 2026: Grant or award of AARD derivative securities (Form 4, code A).
- Jun 26, 2026: Grants or awards of NTRA shares (2 lines, Form 4, code A).
- Jun 12, 2026: Option exercise of TVTX shares (Form 4, code M).
- Jun 12, 2026: Open-market sale of TVTX shares (Form 4, code S).
- May 19, 2026: Grant or award of TVTX shares (Form 4, code A).
Other insiders filing for Aardvark Therapeutics, Inc. (AARD)
- Zhang Zhongwei, Director
- Sun Nelson
- Chi Jeffrey, Director
- Graf Susan E, Director
- Tong Victor Edward Jr, Director
- Jaiman Manasi, Chief Medical Officer